Home
World Journal of Biology Pharmacy and Health Sciences
ISSN Approved | International, Peer reviewed, Referred, Open access Journal

Main navigation

  • Home
    • Journal Information
    • Abstracting and Indexing
    • Editorial Board Members
    • Reviewer Panel
    • Journal Policies
    • WJBPHS CrossMark Policy
    • Publication Ethics
    • Current Issue
    • Issue in Progress
    • Past Issues
    • Instructions for Authors
    • Article processing fee
    • Track Manuscript Status
    • Get Publication Certificate
    • Become a Reviewer panel member
    • Join as Editorial Board Member
  • Contact us
  • Downloads

ISSN Approved Journal | | IMPACT FACTOR 8.16 | | eISSN: 2582-5542 | |  Free Crossref DOI 

Fast Publication within 2 days | | Low Article Processing Charges | | Peer Reviewed and Referred Journal

Research and review articles are invited for publication in September 2026 (Volume 27, Issue 3) Submit Paper

Cardiovascular disease risk reduction for all-cause mortality benefit in low-risk individuals

Breadcrumb

  • Home
  • Cardiovascular disease risk reduction for all-cause mortality benefit in low-risk individuals

Saghana Baran Chakrabortty *

4331 Woodland Drive, La Mesa, California 91941.

Research Article
 
World Journal of Biology Pharmacy and Health Sciences, 2024, 20(01), 270–275.
Article DOI: 10.30574/wjbphs.2024.20.1.0742
DOI url: https://doi.org/10.30574/wjbphs.2024.20.1.0742

Received on 31 August 2024; revised on 10 October 2024; accepted on 12 October 2024

Background: Current recommendations for the primary prevention of cardiovascular disease (CVD) are based solely on 10-year CVD risk assessment. However, CVD mortality is not compared with all-cause mortality, which could provide insights into the potential benefits of CVD risk interventions on overall mortality.
Methods: CVD risk for average American white and black males and females is calculated using the 2013 American Heart Association equations. CVD death risk is determined by combining CVD risk with the death rate following a CVD diagnosis. This CVD death risk is then compared with all-cause mortality data from National Vital Statistics Reports. A larger ratio indicates that most deaths are attributed to CVD, suggesting that intervention may be more beneficial.
Results: The CVD mortality ratio is highest for white men and lowest for black men, indicating that white male likely to benefit most from CVD risk modification, while black males will benefit the least. Additionally, the ratio, and the potential benefit, decreases with age for all groups, especially after the age of 70.
Conclusion: For the average U.S. population without a CVD diagnosis, the potential mortality benefit from interventions targeting CVD risk factors varies significantly based on patient characteristics such as race, age, and gender. The potential benefit is greatest for white males and decreases with age for all groups.

Cardiovascular Mortality; All-Cause Mortality; Risk Reduction; Average American

https://wjbphs.com/sites/default/files/fulltext_pdf/WJBPHS-2024-0742.pdf

Preview Article PDF

Saghana Baran Chakrabortty. Cardiovascular disease risk reduction for all-cause mortality benefit in low-risk individuals. World Journal of Biology Pharmacy and Health Sciences, 2024, 20(01), 270–275. Article DOI: https://doi.org/10.30574/wjbphs.2024.20.1.0742

Get Certificates

Get Publication Certificate

Download LoA

Check Corssref DOI details

Issue details

Issue Cover Page

Editorial Board

Table of content


Copyright © Author(s). All rights reserved. This article is published under the terms of the Creative Commons Attribution 4.0 International License (CC BY 4.0), which permits use, sharing, adaptation, distribution, and reproduction in any medium or format, as long as appropriate credit is given to the original author(s) and source, a link to the license is provided, and any changes made are indicated.


Copyright © 2026 World Journal of Biology Pharmacy and Health Sciences (WJBPHS) - All rights reserved

Developed & Designed by VS Infosolution